Literature DB >> 20960273

Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ.

Mehdi Anvari1, Omid Khalilzadeh, Alireza Esteghamati, Fatemeh Momen-Heravi, Mahdi Mahmoudi, Shadi Abdar Esfahani, Armin Rashidi, Aliakbar Amirzargar.   

Abstract

The role of genetic factors in the pathogenesis of Graves' disease (GD) is not clear. The purpose of this study was to investigate the association between single nucleotide polymorphisms in pro-inflammatory cytokine genes and GD in Iranian patients. A case-control hospital-based study was carried out on 107 GD patients and 140 healthy controls. Cytokine typing was performed by polymerase chain reaction with sequence-specific primers (PCR-SSP) assay. The allele and genotype frequencies of the following cytokine genes were determined: TNF-α (-308A/G, -238A/G), IL-2 (-330T/G, +166G/T), IL-6 (-174C/G, A/G nt565), IL-12 (-1188A/C), and IFN-γ (UTR 5644A/T). The following alleles and genotypes were significantly overrepresented in patients: TNF-α -308A allele (P < 0.01) and AA genotype (P < 0.05), IL-2 -330G allele (P < 0.01) and GG genotype (P < 0.01), IL-6 -174C allele (P < 0.01) and CC genotype (P < 0.01), IL-12 -1188C allele (P < 0.01) and CC genotype (P < 0.01), IFN-γ UTR5644T allele (P < 0.01) and TT genotype (P < 0.01). In conclusion, this is the first study to show a significant association between GD and IL-2 -330G, IL-12 -1188C, and IFN-γ UTR 5644T alleles. Our results support the hypothesis that polymorphism in pro-inflammatory cytokines might be involved in predisposition to GD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960273     DOI: 10.1007/s12020-010-9311-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  28 in total

Review 1.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity.

Authors:  J J Corrales; A Orfao; A López; M T Mories; J M Miralles; J Ciudad
Journal:  Cytometry       Date:  1997-06-15

3.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

4.  A systematic approach to the assessment of known TNF-alpha polymorphisms in Graves' disease.

Authors:  M J Simmonds; J M Heward; J M M Howson; H Foxall; R Nithiyananthan; J A Franklyn; S C L Gough
Journal:  Genes Immun       Date:  2004-06       Impact factor: 2.676

5.  Cytokine promoter polymorphisms in Taiwanese patients with Graves' disease.

Authors:  Ming-Yuh Shiau; Chien-Ning Huang; Tzi-Peng Yang; Yi-Ching Hwang; Kan-Jen Tsai; Chieh-Ju Chi; Yih-Hsin Chang
Journal:  Clin Biochem       Date:  2006-12-05       Impact factor: 3.281

Review 6.  A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis.

Authors:  Takahiko Horiuchi; Chikako Kiyohara; Hiroshi Tsukamoto; Takuya Sawabe; Isao Furugo; Seiji Yoshizawa; Akira Ueda; Yoshifumi Tada; Tadashi Nakamura; Yasutaka Kimoto; Hiroki Mitoma; Shinichi Harashima; Shigeru Yoshizawa; Terufumi Shimoda; Seiich Okamura; Kohei Nagasawa; Mine Harada
Journal:  Ann Rheum Dis       Date:  2006-10-06       Impact factor: 19.103

7.  Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour?

Authors:  E Louis; M Peeters; D Franchimont; L Seidel; F Fontaine; G Demolin; F Croes; P Dupont; L Davin; S Omri; P Rutgeerts; J Belaiche
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

8.  A polymorphism of interferon-gamma gene associated with changes of anti-thyrotropin receptor antibodies induced by antithyroid drug treatment for Graves' disease in Japanese patients.

Authors:  Tomoka Fukutani; Yuji Hiromatsu; Hiroo Kaku; Ikuyo Miyake; Tokunori Mukai; Yoichi Imamura; Shusuke Kohno; Naoko Takane; Shingo Shoji; Shuichi Otabe; Kentaro Yamada
Journal:  Thyroid       Date:  2004-02       Impact factor: 6.568

9.  Association of tumour necrosis factor alpha (TNF-alpha) polymorphisms with Graves' disease: A meta-analysis.

Authors:  Ni Li; Zongguang Zhou; Xuyang Liu; Yi Liu; Junjun Zhang; Liang Du; Maoling Wei; Xiaoming Chen
Journal:  Clin Biochem       Date:  2008-04-26       Impact factor: 3.281

10.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

View more
  9 in total

1.  Regulatory T cells but not T helper 17 cells are modulated in an animal model of Graves' hyperthyroidism.

Authors:  Jin Zhou; Mei Bi; Chenling Fan; Xizhu Song; Rong Yang; Shujie Zhao; Li Li; Yushu Li; Weiping Teng; Zhongyan Shan
Journal:  Clin Exp Med       Date:  2011-05-05       Impact factor: 3.984

2.  Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.

Authors:  Fatemeh Rajaii; Allison N McCoy; Terry J Smith
Journal:  Expert Rev Ophthalmol       Date:  2014-06

3.  Associations between gut microbiota and thyroidal function status in Chinese patients with Graves' disease.

Authors:  J Chen; W Wang; Z Guo; S Huang; H Lei; P Zang; B Lu; J Shao; P Gu
Journal:  J Endocrinol Invest       Date:  2021-01-22       Impact factor: 4.256

4.  Association of IL12B polymorphisms with susceptibility to Graves ophthalmopathy in a Taiwan Chinese population.

Authors:  Yu-Huei Liu; Ching-Chu Chen; Li-Ling Liao; Lei Wan; Chang-Hai Tsai; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2012-11-19       Impact factor: 8.410

5.  Polymorphisms in the TNFA and IL6 genes represent risk factors for autoimmune thyroid disease.

Authors:  Cecília Durães; Carla S Moreira; Inês Alvelos; Adélia Mendes; Liliana R Santos; José Carlos Machado; Miguel Melo; César Esteves; Celestino Neves; Manuel Sobrinho-Simões; Paula Soares
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

6.  Association between polymorphism within interleukin related genes and Graves' disease: a meta-analysis of 22 case-control studies.

Authors:  Yaqin Tu; Guorun Fan; Tianshu Zeng; Xiong Cai; Wen Kong
Journal:  Oncotarget       Date:  2017-08-10

7.  Association of TNF-α promoter polymorphism and Graves' disease: an updated systematic review and meta-analysis.

Authors:  Yaqin Tu; Guorun Fan; Tianshu Zeng; Xiong Cai; Wen Kong
Journal:  Biosci Rep       Date:  2018-03-21       Impact factor: 3.840

8.  Tocilizumab for thyroid eye disease.

Authors:  Shirin Hamed Azzam; Swan Kang; Mario Salvi; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

9.  Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy.

Authors:  Edina Kishazi; Marianne Dor; Simone Eperon; Aurélie Oberic; Natacha Turck; Mehrad Hamedani
Journal:  Sci Rep       Date:  2018-07-17       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.